AssetMark Inc’s Citius Pharmaceuticals CTXR Stock Holding History

AssetMark Inc’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-372	Closed	-$225	–	3795
2026 Q2	$225	Hold	372	–	–	﹤0.01%	3412
2026 Q1	$335	Buy	+372	New	+$300	﹤0.01%	3251

Other funds holding CTXR

Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return

Asset Advisory Group Kinnelon, New Jersey $232M AUM 16.51% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.25% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Princeton Global Asset Management Princeton, New Jersey $692M AUM 20.31% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

AssetMark Inc's CTXR Position: Q3 2026 in Review

AssetMark Inc sold out of Citius Pharmaceuticals (CTXR) in Q3 2026, closing a stake of 372 shares — an estimated $225 sold.

AssetMark Inc first reported a position in CTXR in Q1 2026 and held it in 2 quarters. The position peaked at $335 in Q1 2026. 7 funds tracked by Wall St. Rank hold CTXR as of Q3 2026.

AssetMark Inc reported no remaining Citius Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
AssetMark Inc sold 372 Citius Pharmaceuticals shares in Q3 2026, an estimated $225.
AssetMark Inc first reported a position in Citius Pharmaceuticals in Q1 2026 and held it in 2 quarters.
AssetMark Inc's Citius Pharmaceuticals position peaked at $335 in Q1 2026.
7 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.